Zynerba Pharmaceuticals Shares Outstanding 2014-2018 | ZYNE

Zynerba Pharmaceuticals shares outstanding from 2014 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Zynerba Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2018 15
2017 13
2016 9
2015 4
2014 1
2013 0
Zynerba Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
Q4 2018 15
Q3 2018 17
Q2 2018 14
Q1 2018 13
Q4 2017 13
Q3 2017 13
Q2 2017 13
Q1 2017 12
Q4 2016 9
Q3 2016 9
Q2 2016 9
Q1 2016 9
Q4 2015 4
Q3 2015 6
Q2 2015 1
Q1 2015 1
Q4 2014 1
Q3 2014 1
Q2 2014 1
Q1 2014 0
Q4 2013 0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.170B $0.000B
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $46.669B 8.40
Teva Pharmaceutical Industries (TEVA) Israel $14.602B 5.04
Mylan (MYL) United Kingdom $13.853B 5.86
Bausch Health Cos (BHC) Canada $8.091B 5.75
Dr Reddy's Laboratories (RDY) India $6.770B 27.00
Supernus Pharmaceuticals (SUPN) United States $1.887B 17.51
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.523B 2.47
Amphastar Pharmaceuticals (AMPH) United States $0.943B 87.65
Homology Medicines (FIXX) United States $0.832B 0.00
CymaBay Therapeutics (CBAY) United States $0.718B 0.00
Voyager Therapeutics (VYGR) United States $0.626B 0.00
Assembly Biosciences (ASMB) United States $0.423B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.410B 0.00
Akorn (AKRX) United States $0.348B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.172B 0.00
Sol-Gel Technologies (SLGL) Israel $0.132B 0.00
Acasti Pharma (ACST) Canada $0.074B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.061B 0.00
Agile Therapeutics (AGRX) United States $0.060B 0.00
Teligent (TLGT) United States $0.044B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00
Evoke Pharma (EVOK) United States $0.013B 0.00